title: Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders.
abstract: Cardiovascular diseases (CVDs), primarily myocardial infarction (MI), atherosclerosis, hypertension and congestive heart failure symbolize the foremost cause of death in almost all parts of the world. Besides the traditional therapeutic approaches for the management of CVDs, newer innovative strategies are also emerging on the horizon. Recently, gene silencing via small interfering RNA (siRNA) is one of the hot topics amongst various strategies involved in the management of CVDs. The siRNA mechanism involves natural catalytic processes to silence pathological genes that are overexpressed in a particular disease. Also the versatility of gene expression by siRNA deciphers a prospective tactic to down-regulate diseases associated gene, protein or receptor existing on a specific disease target. This article reviews the application of siRNA against CVDs with special emphasis on gene targets in combination with delivery systems such as cationic hydrogels, polyplexes, peptides, liposomes and dendrimers.
authors.forename: Rahul
authors.initials: R
authors.lastname: Maheshwari
authors.forename: Muktika
authors.initials: M
authors.lastname: Tekade
authors.forename: Piyoosh A
authors.initials: PA
authors.lastname: Sharma
authors.affiliation: School of Pharmacy, Department of Pharmaceutical Technology, International Medical University, JalanJalil Perkasa 19, 57000 Kuala Lumpur, Malaysia. rakeshtekade@gmail.com.
authors.forename: Rakesh Kumar
authors.initials: RK
authors.lastname: Tekade
mesh_terms: D002318:Cardiovascular Diseases / Q000235:genetics* / Q000628:therapy*; D004337:Drug Carriers / Q000737:chemistry*; D020868:Gene Silencing; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D053758:Nanoparticles / Q000737:chemistry*; D036103:Nanotechnology; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics*
chemical_list: D004337:Drug Carriers; D034741:RNA, Small Interfering